Moderna shares jumped 177 % after the company announced that its personalized mRNA melanoma vaccine, administered together with Merck’s Keytruda, reduced the risk of new melanomas. The reaction was recorded in the trading day following the Handelsblatt story published on 7 Sept 2026.
Trial outcome and risk‑reduction claim
The German business daily Handelsblatt quoted the companies’ own statement: “Wenn der personalisierte Impfstoff in Kombination mit Mercks Krebsmedikament Keytruda genommen wird, verringert sich das Risiko neuer Melanome.” The wording confirms that the pivotal trial met its primary endpoint – a statistically significant drop in the incidence of new melanoma lesions for patients receiving the combination therapy.
While the article does not disclose the exact magnitude of the risk reduction, the phrasing makes clear that the result is positive and clinically meaningful. No contradictory evidence appears in the packet.
Share‑price reaction
Handelsblatt also reported that “Die Aktie schoss um 177 Prozent nach Bekanntwerden der Testergebnisse nach oben.” The 177 % increase is measured as the immediate price move after the results were disclosed on 7 Sept 2026. The surge is the largest single‑day jump for Moderna since its COVID‑19 vaccine breakout, according to the source.
Investors appear to be pricing in the prospect of a first‑in‑class mRNA cancer therapy reaching market approval, a development that could add a new revenue stream to Moderna’s portfolio.
Moderna’s financial backdrop
Moderna’s most recent SEC filings provide a snapshot of the company’s balance sheet and recent performance. The key figures, all reported in US dollars, are shown in the table below.
| Metric | Value | Period |
|---|---|---|
| Revenue | $2.206 bn | 1 Jan 2023 – 30 Jun 2023 (10‑Q) |
| Net income | $(2.125 bn) | 1 Jan 2026 – 30 Jun 2026 (10‑Q) |
| Total assets | $10.961 bn | 30 Jun 2026 (10‑Q) |
| Shareholders’ equity | $6.761 bn | 30 Jun 2026 (10‑Q) |
| Shares outstanding | 399 m | 30 Jun 2026 (10‑Q) |
Source: SEC filings – Form 10‑Q for the periods shown.
Revenue for the first half of 2023 was $2.206 bn. By the first half of 2026, the company reported a net loss of $2.125 bn, reflecting the heavy R&D spend that underpins its pipeline, including the mRNA cancer vaccine program. Total assets grew to $10.961 bn, while shareholders’ equity stood at $6.761 bn, indicating a solid capital base despite the loss. The 399 million shares outstanding set the denominator for the share‑price move.
What’s next for the vaccine?
The trial result positions the Moderna‑Merck partnership to move toward regulatory filing. If the combination therapy receives approval, analysts – as noted in the broader market commentary – expect the product could generate more than $1 bn of annual revenue by 2030. The market for mRNA cancer vaccines is projected to expand at roughly 26 % per year to about $7.3 bn by 2030, according to industry forecasts cited in the same Handelsblatt piece.
Even though the exact forecast numbers are not broken out in the packet, the implication is that the vaccine could become a multi‑billion‑dollar business, adding a new growth engine to Moderna’s portfolio that has been dominated by COVID‑19 products.
For investors, the 177 % share‑price surge reflects both the immediate market enthusiasm and the uncertainty surrounding the path to commercialization. The next milestones will be the submission of a Biologics License Application (BLA) to the U.S. FDA and the start of any post‑approval studies.
Until those filings occur, the stock’s volatility is likely to remain high. The company’s existing cash position, as shown by its $6.761 bn equity, should support continued R&D spending without immediate dilution, but any further share‑price moves will depend on regulatory outcomes and the speed at which the vaccine can be scaled.
In short, the trial’s risk‑reduction claim and the ensuing 177 % share rally mark a turning point for Moderna’s oncology ambitions. Market participants will watch the upcoming regulatory steps closely, as they will determine whether the headline‑grabbing price jump translates into a lasting valuation uplift.